Linked Life Data

3772412

Source:http://linkedlifedata.com/resource/pubmed/id/3772412

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1986-12-4
pubmed:abstractText
The effects of cyproheptadine were studied in two patients with spastic paresis. The study consisted of two phases: a control phase (no medication) and a cyproheptadine phase (8 mg t.i.d.). The effects were evaluated from electromyographic (EMG) and kinematic analysis of treadmill walking with a portion of body weight supported, and from clinical examination and subjective assessments. Episodes of spontaneous spasms and elicited clonus were reduced with cyproheptadine. Improvement in locomotor function was evidenced by a decreased cycle duration, more regular foot-floor contact, functional joint excursions, and increased walking speed. In addition, a tonic EMG activity pattern was replaced by phasic muscle activation in the proximal extensors especially. Selective proximal movements were unmasked (hip flexion) and certain functional activities (transfers, dressing) were facilitated. The results support the role of cyproheptadine as an antispastic medication. Study of the short-term and long-term benefits of cyproheptadine is continuing.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0340-5354
pubmed:author
pubmed:issnType
Print
pubmed:volume
233
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
311-4
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Quantitative assessment of the effect of cyproheptadine on spastic paretic gait: a preliminary study.
pubmed:publicationType
Journal Article, Case Reports, Research Support, Non-U.S. Gov't